Table 2.
Applicability of Pharmacogenomics to Most Frequently Changed Medications
| Medication | Prescriptions, n (at baseline) | Medication Changes,a n (%)b | Influencedc by PGx, n (%) |
|---|---|---|---|
| Atorvastatin | 301 | 35 (4.3) | 14 (40.0) |
| Lisinoprild | 240 | 35 (4.3) | n/ad |
| Amlodipine | 232 | 34 (4.2) | 10 (29.4) |
| Hydrochlorothiazide | 258 | 34 (4.2) | 9 (26.5) |
| Omeprazole | 144 | 26 (3.2) | 12 (46.2) |
| Chlorthalidoned | 42 | 23 (2.8) | n/ad |
| Aspirin | 524 | 22 (2.7) | 4 (18.2) |
| Esomeprazole | 73 | 22 (2.7) | 9 (40.9) |
| Fluticasone Propionate | 136 | 20 (2.5) | 2 (10.0) |
| Metoprolol | 196 | 20 (2.5) | 6 (30.0) |
a
includes new medications, dose changes, and discontinuations;
b
reflects each drug’s changes as a percentage of all total medication changes in the study;
c
see Methods for determination of prescriptions influenced by PGx;
d
no clinically actionable pharmacogenomic information existed for this drug, so attribution of influence of pharmacogenomics for this drug was not applicable (n/a);
PGx = pharmacogenomics